Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential

SIMPLE SUMMARY: Most breast cancers express the estrogen, progesterone, and/or HER2 receptors and patients are treated with inhibitors targeting these receptors. Triple negative breast cancers (TNBCs) lack these receptors and thus patients with TNBC do not benefit from existing targeted therapies. T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Fermaintt, Charles S., Peramuna, Thilini, Cai, Shengxin, Takahashi-Ruiz, Leila, Essif, Jacob Nathaniel, Grant, Corena V., O’Keefe, Barry R., Mooberry, Susan L., Cichewicz, Robert H., Risinger, April L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8201195/
https://ncbi.nlm.nih.gov/pubmed/34200174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112834
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak